AGEs and diseases

Key publications
Early- and advanced non-enzymatic glycation in diabetic vascular complications: the search for therapeutics.
Ceriello A. et al. 2009. The Journal of Clinical Endocrinology & Metabolism Vol. 94(2) 410-415
The "Metabolic Memory": Is More Than Just Tight Glucose Control Necessary to Prevent Diabetic Complications?

Publications
Willemsen S. et al. Heart Fail Rev. 2011; Epub
Advanced glycation end-products, a pathophysiological pathway in the cardiorenal syndrome.
Glycation in diabetic nephropathy.
Lipid glycation and protein glycation in diabetes and atherosclerosis.
Risk factors and early detection of atherosclerosis in rheumatoid arthritis.

Does hepatitis C increase the accumulation of advanced glycation end products in haemodialysis patients?
Increased accumulation of advanced glycation endproducts in patients with Wegener’s granulomatosis.

Advanced Glycation End Products and their receptor RAGE in systemic autoimmune diseases - an inflammation propagating factor contributing to accelerated atherosclerosis.

Advanced Glycation End Products in Renal Failure: An Overview

Gerrits E. et al. Nephrology Dialysis and Transplantation November 25, 2008
AGEs, autofluorescence and renal failure

Meerwaldt R et al, Eur J Vasc Endovasc Surg 2008:36, 125-131
Clinical relevance of advanced glycation endproducts for vascular surgery

Advanced Glycation Endproducts in Chronic Heart Failure

Stenvinkel P, Nephr Dial Transpl; 2003: 18 (suppl 8)17-22
Anaemia and inflammation: what are the implications for nephrologist?

Stenvinkel P, Nephr Dial Transpl 2002:17 (suppl8)33-38
Inflammation in end-stage renal failure: could be treated?

Stenvinkel P. Nephr Dial Transpl. 2002:17 (suppl 8)16-24
Anaemia, rHuEPO resistance, and cardiovascular disease in end-stage renal failure: links to inflammation and oxidative stress
Dialysis related amyloidosis: Pathogenesis focusing on AGE modification.

oxidative stress in hemodialysis patients: what are the determining factors.

Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications.

Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation.

Diabetic vascular disease: it's all the RAGE.

Role of advanced glycation end products in diabetic nephropathy.

Atherosclerosis and diabetes: the RAGE connection.

New markers of advanced damage caused by oxidative and carbonyl stress.

Advanced glycation end products and advanced oxidation protein products in hemodialyzed patients.

The AGE-RAGE system and diabetic nephropathy.

Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease.

The advanced glycation end product Nepsilon-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes.

The role of advanced glycation end products in retinal microvascular leukostasis.

Advanced glycation: how are we progressing to combat this web of sugar anomalies in diabetic nephropathy.

Role of advanced glycation end products in diabetic nephropathy.

Advanced Glycation End Products in Alzheimer's Disease and Other Neurodegenerative diseases.

Cooper ME. American Journal of Hypertension, 17:31S–38S, August 2004
Importance of Advanced Glycation End Products in Diabetes-Associated Cardiovascular and Renal Disease.
**Serum Levels of Advanced Glycation End Products Are Associated With Left Ventricular Diastolic Function in Patients With Type 1 Diabetes**

**Impaired Retinal Angiogenesis in Diabetes: Role of Advanced Glycation End Products and Galectin-3**

**The Maillard Reaction in Eye Diseases**

**Advanced Glycation Endproducts in Human Diabetic and Non-Diabetic Cataractous Lenses**

**Advanced Glycation End Products and Diabetic Nephropathy**

**Low-Molecular Weight Advanced Glycation End Products: Markers of Tissue AGE Accumulation and More?**

**A Role for Advanced Glycation End Products in Diminished Bone Healing in Type 1 Diabetes**

**Advanced Glycation End producs and Osteoarthritis**

**Accumulation of Advanced Glycation Endproducts Reduces Chondrocyte-Mediated Extracellular Matrix Turnover in Human Articular Cartilage**

Bohlender JM. et al. AJP - Renal 289:645-659, 2005  
**Advanced Glycation End Products and the Kidney**

**Advanced Glycation End-Products and the Progress of Diabetic Vascular Complications**

**Advanced Glycation End-Products and Advanced Oxidation Protein Products in Patients with Diabetes Mellitus**

**Below the Radar: Advanced Glycation End Products that Detour “around the side”**

Tan K, et al. Diabetes Care, Vol 27 Number 1, January 2004 223-228  
**Association Between Acute-Phase Reactants and Advanced Glycation End Products in Type 2 Diabetes**

Monnier V. Biochemistry and Biophysics 419 (2003) 1-15  
**Intervention against the Maillard reaction in vivo**

**Advanced glycation end-products and methionine sulphoxide in skin collagen of patients with type 1 diabetes.**

**Potential cardiovascular risk factors in chronic kidney disease: AGEs, total homocysteine and metabolites and the C-reactive protein**
Glucose, Advanced Glycation End Products, and Diabetes Complications: what Is New and What Works